Minapharm Pharmaceuticals (CAI:MIPH) Other Operating Expense: E£2 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
52 GF Score
Price E£735.41
GF Value E£365.36
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Other Operating Expense?

Minapharm Pharmaceuticals CAI:MIPH -1.03% 52 Other Operating Expense is E£2 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 52/100 and a GF Value™ of E£365.36 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's Other Operating Expense for the three months ended in Dec. 2025 was E£-329 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was E£2 Mil.

Minapharm Pharmaceuticals's quarterly Other Operating Expense increased from Jun. 2025 (E£34 Mil) to Sep. 2025 (E£118 Mil) but then declined from Sep. 2025 (E£118 Mil) to Dec. 2025 (E£-329 Mil).

Minapharm Pharmaceuticals's annual Other Operating Expense declined from Dec. 2023 (E£362 Mil) to Dec. 2024 (E£160 Mil) and declined from Dec. 2024 (E£160 Mil) to Dec. 2025 (E£116 Mil).

Minapharm Pharmaceuticals Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Other Operating Expense Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
151.28 220.15 362.43 159.89 116.41

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.20 178.42 34.22 118.22 -328.66
CAI:MIPH
52GF Score
Minapharm Pharmaceuticals CAI:MIPH
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of E£2 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Other Operating Expense of E£2 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Other Operating Expense too high?
Minapharm Pharmaceuticals' current Other Operating Expense is E£2 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Other Operating Expense compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Other Operating Expense of E£2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Other Operating Expense is E£2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£365.36, compared to a current price of E£735.41 — trading 101.3% above its estimated fair value. The current Other Operating Expense is E£2 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Other Operating Expense is E£2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£735.41 is trading 101.3% above its estimated GF Value™ of E£365.36. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Other Operating Expense: E£2 Mil
  • GF Value™: E£365.36 vs. price of E£735.41 (101.3% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
52GF Score

Get the complete analysis for CAI:MIPH

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£735.41
Price
E£365.36
GF Value